text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 17902-23-7 | Product Number: F0635

5-Fluoro-1-(tetrahydro-2-furfuryl)uracil


Purity: >98.0%(HPLC)(N)
Synonyms:
  • Tegafur
Product Documents:
5G
29,00 €
1   6  
25G
93,00 €
Contact Us 1  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number F0635
Purity / Analysis Method >98.0%(HPLC)(N)
Molecular Formula / Molecular Weight C__8H__9FN__2O__3 = 200.17 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
CAS RN 17902-23-7
Reaxys Registry Number 525766
PubChem Substance ID 87559743
Merck Index (14) 9112
MDL Number

MFCD00012351

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(with Total Nitrogen) min. 98.0 %
Melting point 167.0 to 171.0 °C
NMR confirm to structure
Properties (reference)
Melting Point 169 °C
GHS
Pictogram Pictogram Pictogram
Signal Word Danger
Hazard Statements H300 : Fatal if swallowed.
H373 : May cause damage to organs through prolonged or repeated exposure.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P260 : Do not breathe dust.
P270 : Do not eat, drink or smoke when using this product.
P264 : Wash skin thoroughly after handling.
P314 : Get medical advice/ attention if you feel unwell.
P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.
Related Laws:
EC Number 241-846-2
RTECS# YR0450000
Transport Information:
UN Number UN2811
Class 6.1
Packing Group II
HS Number 2940000080
Application
Tegafur: A Prodrug of an Active Antitumor 5-FU

Tegafur is a prodrug that is metabolized by cytochrome P 450 to an active antitumor 5-FU [F0151]. Tegafur is often used as combined agents such as UFT (tegafur and uracil [U0013] at a molar ratio of 1:4) or S-1 (tegafur, gimeracil [C2243] and potassium oxonate [O0164] at a molar ratio of 1:0.4:1) to increase the plasma and tumor 5-FU concentrations. Determination of the combined agents in plasma is important to evaluate the safety and efficacy of them. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.